PFO
ORTX

Pathstone Family Office’s Orchard Therapeutics plc American Depositary Shares ORTX Stock Holding History

Pathstone Family Office’s Portfolio ORTX Stock Details ORTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-440
Closed -$26K – 1029
2020
Q2 		$26K Hold
440
– – ﹤0.01% 396
2020
Q1 		$33K Buy
+440
New +$50.7K ﹤0.01% 360

Other funds holding ORTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Pathstone Family Office's ORTX Position: Q3 2020 in Review

Pathstone Family Office sold out of Orchard Therapeutics plc American Depositary Shares (ORTX) in Q3 2020, closing a stake of 440 shares — an estimated $26K sold.

Pathstone Family Office first reported a position in ORTX in Q1 2020 and held it in 2 quarters. The position peaked at $33K in Q1 2020. 72 funds tracked by Wall St. Rank hold ORTX as of Q3 2020.

  • Pathstone Family Office reported no remaining Orchard Therapeutics plc American Depositary Shares position as of Q3 2020 after selling out during the quarter.
  • Pathstone Family Office sold 440 Orchard Therapeutics plc American Depositary Shares shares in Q3 2020, an estimated $26K.
  • Pathstone Family Office first reported a position in Orchard Therapeutics plc American Depositary Shares in Q1 2020 and held it in 2 quarters.
  • Pathstone Family Office's Orchard Therapeutics plc American Depositary Shares position peaked at $33K in Q1 2020.
  • 72 funds tracked by Wall St. Rank held Orchard Therapeutics plc American Depositary Shares as of Q3 2020.

Based on Pathstone Family Office's 13F filing for Q3 2020, filed 12 Nov 2020.